Questions

What is already known about this topic?
 Considerable effort has been devoted to developing an effective non-invasive method of monitoring disease progression and outcome among cancer patients. One method is multimarker qRT-PCR used to detect circulating tumour cells in patient blood. In breast, colorectal and prostate cancer circulating tumour cells correlate with both disease progression and poor treatment outcome. Circulating cell analysis in melanoma has had varied success; despite the capacity to detect cells the appropriate markers remain undefined.
What does this study add?
 This is the first application of ABCB5 as a marker of circulating melanoma cells, incorporated into a multi marker qRT-PCR test of melanoma patient blood. Expressed by a subset of melanoma cells with a stem cell phenotype, its detection in this study, along with MLANA a melanocyte marker, correlated with disease recurrence, suggesting both stem and non-stem cell phenotypes are present in patient peripheral blood. MCAM expression is shown for the first time to correlate with negative treatment outcomes.
Introduction
Cutaneous melanoma is a tumour originating from normal skin melanocytes. Global incidence of melanoma is increasing 1 , with an estimated 70,230 new cases annually in the USA 2 . Melanoma has a high metastatic potential 3 and metastatic melanoma is difficult to treat . It is important therefore to find methods of detecting melanoma spread at early stages for more accurate treatment and prediction of prognosis.
A staging system was devised by the American Joint Committee on Cancer (AJCC) based on histological features of the primary lesion, and the presence of nodal and/or systemic metastases in advanced disease 3 . Due to increased awareness, most patients present with thin, localised melanoma which is usually curable by surgical resection. However, approximately 5% of patients with lesions <1 mm thick, 25-40% with 2 to 4 mm lesions and 50-75% with lesions > 4 mm develop metastatic disease and die within ten years 3 . Patients diagnosed with regional and distant metastases have 10 year survival rates of 64% and 16% respectively 4 .
Patients may suffer relapse following disease free periods of ten years or more 5, 6 . Evidently then, diagnosing patients as clinically disease free after surgical removal of early stage melanomas, may be inaccurate, since tumour cells dispersed into the bloodstream may remain dormant, prior to formation of distant metastases 7 .
Considerable research into the detection of circulating tumour cells in the blood of patients with breast, colorectal and prostate cancer has shown that the presence of these cells correlates with both disease progression and poor outcome [8] [9] [10] [11] [12] [13] [14] [15] [16] . For melanoma, circulating cell analysis has not been successfully utilised clinically. Although several articles have indicated their usefulness [17] [18] [19] [20] [21] [22] , markers and methodology remain controversial. Moreover, it is unclear whether circulating melanoma stem cells are prognostic 23 or whether all circulating melanoma cells have metastatic potential 24 .
Here we used multimarker qRT-PCR to investigate the phenotype of circulating cells in melanoma patients. Given qRT-PCR sensitivity, it is suitable for assessment of rare circulating melanoma cells 25 and multiple markers are essential given the heterogeneous nature of melanoma cells 18, 26 [32] [33] [34] , and the PAX3d isoform is highly expressed in melanoma 35 .
ABCB5 a stem cell marker, marks a subset of rare, chemoresistent melanoma stem cells 24, 31, 36 , while MCAM is a marker of melanoma tumour progression 34 .
We show that circulating tumour cells are detectable at all stages of disease and persist long after treatment. Certain circulating cells, specifically those marked by MCAM expression, correlated with a poor treatment outcome, while ABCB5 and MLANA, correlated with disease progression and could aid in monitoring disease status.
Material and Methods
Patient cohort
Patient (230) 
Melanoma cell lines
Human melanoma cell line A2058 cells (EACC: 91100402), were grown in DMEM media containing 10% heat inactivated foetal bovine serum (Invitrogen) in a T75-cm 2 flask (Greiner) until cells were ~70% confluent.
Blood Collection, RNA Isolation and Amplification Protocols
At venipuncture, the first 4 mL of blood was discarded to avoid epithelial contamination 37 .
2.5mL of whole blood was then collected into a PAXgene Blood RNA Tube (PreAnalytiX), containing RNA stabilisers 38 .
Total RNA was isolated using the PAXgene Blood RNA kit (Qiagen) and DNase treated (DNA-free Kit, Ambion). RNA was quantified and the integrity was qualified (Agilent 2100
Bioanalyser, Agilent Technologies). Samples with insufficient RNA levels (RIN <8) were Table   1 ). Using an iCycler iQ5 Real-Time Thermocycler (BIO-RAD) incubation was as per the manufacturer's instructions.
To prevent contamination all PCR reactions contained Uracil-N-glycosylase to prevent reamplification of carryover PCR products 39 and different steps were performed in separate UV treatable areas. Tm determination and gel electrophoresis confirmed the expected size and identity of PCR products.
GAPDH, our internal reference for RT efficiency, is not up regulated in melanoma tissues or cultured cells relative to normal samples 40 ; samples with insufficient levels were excluded.
Every assay included a standard curve, negative controls (NTC and reverse transcription control), positive control (A2058 cell line) and cDNA from a single healthy control.
Standard Curve
A standard curve to quantify mRNA copy number, was constructed using larger PCR products that included the target sequence used in qRT-PCR assays. For each standard, an end point PCR primer set was designed (Supplementary Table 2 minute. PCR products were purified after agarose gel electrophoresis using the freezesqueeze method 41 . Resulting stock template solutions were quantified by spectrophotometric analysis (Nanodrop, Thermo Scientific) and diluted into eight tenfold serial dilutions (10 1 -10 8 copies/µL) from which a standard curve for each target was generated on the iCycler iQ5
Real-Time Thermocycler. Amplification efficiency of our target genes were between 96.4 and 100%. Samples were analysed in duplicate with averaged cT values used for relative quantification. Relative mRNA copies for each transcript were calculated by dividing absolute mRNA copies of the target by that of GAPDH.
Statistical Analysis
Pearson chi-square test and Fishers exact test were used to examine statistical significance of marker expression between patient groups and controls. 
Results
Multimarker RT-PCR analysis was used to estimate the phenotype and quantity of circulating cells in patient blood. Marker positivity and level of expression were analysed for correlation with disease presence, stage, recurrence and treatment outcome.
Marker Expression in Patient Blood Relative to Controls:
Melanoma patients (92%, n=212) were significantly more likely to express a melanoma cell marker in blood than were controls (59%, n=89) (p= 0.000, Odds ratio = 4.206, 95% CI 2.305-7.676). The number of markers expressed by participants was important, with 83%
(n=126) of healthy controls expressing either no marker or just one marker, in contrast to melanoma patients, who were highly likely to express two or more markers (72%, n=165)(p=0.012)( Table 1 ). The positive and negative predictive value of expressing a marker, was 70% and 78% respectively. Expression of two or more melanoma markers improved the positive predictive value to 86%, with a negative predictive value of 66%.
To identify the most informative markers, we analysed expression incidence of each marker in patients. MLANA, ABCB5, MCAM, PAX3d, and TGFβ2 were detected in 30% (n=68), 40% (n=90), 47% (n=108), 40% (n=91), and 66% (n=152) of melanoma patients, respectively.
Marker Expression in Patients Relative to Clinical Stage:
To assess marker utility, we analysed marker expression relative to clinical stage. MLANA and ABCB5 were significantly more likely to be expressed in late stage patients (Stages III-IV) (42% and 51%) than in early stage patients (0-II) (23% and 33%) (p=0.003 and p=0.006).
No other markers appeared to be stage related (Table 2) .
Clinical factors including primary location, Clark level, Breslow thickness and ulceration did not correlate with marker expression (Table 3) .
Pearson chi-square test was used to analyse whether the incidence of marker expression in patient blood samples taken within one month of clinical diagnosis differ from samples taken at times greater than one month following diagnosis. For most markers, expression did not differ between samples taken at times less than and greater than one month following diagnosis. TGFβ2 however, was expressed slightly more frequently in samples obtained more than a month following diagnosis (47%, n=187) relative to samples collected within in the first month following diagnosis (32%, n=50) (p=0.001). Samples taken at times greater than one month after diagnosis were as likely to express a marker (79%, n=311), than samples taken within the first month following diagnosis (71%, n=110).
Marker Expression Correlates to Disease Recurrence:
To investigate the prognostic value of our markers, the relationship between marker expression and disease recurrence was analysed. Seventy three patients (32%) experienced recurrence during our study and in these patients, both MLANA and ABCB5 were expressed significantly more frequently (45%, n=33 and 49%, n=36) than in patients without recurrence (23%, n=35, 34%, n=54) (p=0.001 and p=0.031) ( Table 4) . Patients with recurrence expressed 5 markers more commonly (8%, n=6) than patients who experienced no recurrence during our study (1%, n=2) (p=0.013). Patients with recurrence during our study were more likely to express both ABCB5 and MLANA (26%, n=19) than patients without recurrence during the study period (10%, n=15) (p=0.002). Co-expression of MLANA and ABCB5 produced a positive predictive value of 56% and a negative predictive value of 72%.
When divided into stages, 48% of stage III-IV patients with recurrence (n=29) expressed MLANA compared to only 19% of stage III-IV patients without recurrence (n=3) (p=0.033).
There was no correlation between MLANA expression and recurrence in early stage (0-II) patients. Analysing the presence and level of markers relative to time since diagnosis in patients who developed recurrence during our study, revealed markers were present in patient blood at all stages, many years after diagnosis or surgical removal of the primary tumour, even when there were no clinical signs of disease (Table 4) .
Marker Expression in relation to Tumour Burden:
To examine if marker expression correlated with tumour burden, stage III-IV patients were divided into those with one metastasis (n=16) (mean of tumour diameter: 19.8mm±13.2mm 
Marker Expression in Relation to Clinical Treatment:
To analyse the effect of non-surgical treatment on circulating tumour cell phenotypes, marker expression was investigated in 34 patients (15%) who received non-surgical treatment.
Treatments included: radiotherapy (n=29), interferon alfa 2b (n=5), limb infusion (n=1), vaccine (n=4), chemotherapy (n=9) and radio frequency ablation (RFA) (n=1).
Three patients were sampled both before and after their non-surgical treatment, whereas the majority of non-surgically treated patients were sampled during or following treatment. The The majority of the non-surgically treated stage IV samples were collected after non-surgical treatment (n=26). To examine whether the phenotype of circulating melanoma cells reflects the effectiveness of treatment, samples were divided into those from patients who had a negative treatment outcome (n=40) (progression and/or death) and those with a positive outcome (n=22) (disease remained stable or tumour size reduced). The expression of MCAM was significantly more common in patients with a negative treatment outcome with 43% expressing MCAM (n=17), while only 9% of samples from patients with a positive outcome, expressed this marker (n=2) (p=0.006)( Table 5 ). The positive predictive value for MCAM expression as a marker of poor clinical outcome in patients with stage IV melanoma is 89.5%, while the negative predictive value is 46.5%.
Marker Consistency and Serial Blood Collection
21.7% of all acquired blood samples had a technical repeat (second PAXgene Blood RNA tube) taken on the same day. Expression in these samples was highly consistent, with 70% of duplicate samples having identical marker expression (n=273).
Generalised linear modelling was employed to examine serially collected samples (n=140), acquired for each patient at intervals of six months over a period of two years. For the majority of our markers, time was not a significant variable, with marker expression remaining consistent, regardless of sampling time and regardless of stage (Supplementary Table 3 ). For ABCB5 however, expression incidence significantly reduced over time (WaldChi = 16.209, p=0.000) in stage IV patients (Odds ratio: 0.2518, p=0.000, 95% CI 0.131, 0.483), which may represent the effect of non-surgical treatment on ABCB5 expression in stage IV patients.
Discussion:
This study showed that a multi marker qRT-PCR test for melanoma circulating cells correlated with melanoma diagnosis. Very few melanoma patients expressed no markers at all, only 7%. A significant number of healthy controls, however also expressed one marker.
Therefore, patients and controls are best differentiated by the number of markers expressed i.e. by a multi marker test.
Multiple markers were detected at all disease stages, even in early stage patients, however the incidence was lower in these patients than in later stage patients. In contrast to previous papers 18, 42 , the levels and number of markers were not stage related, possibly related to the use of ABCB5 and TGFβ2, both previously unused markers of circulating tumour cells.
TGFβ2 was the most common marker in controls, so cannot be recommended as a single marker for patient analysis.
By contrast, ABCB5, described by Frank and colleagues in 2003 was a highly informative marker 23, 24, 31, 36 . ABCB5 reportedly represents a subset of melanoma cells with a stem cell phenotype and is thought here to represent a subset of heterogeneous circulating melanoma cells present at all disease stages. In this study it was identified as a potential predictor of active recurrence/progression events with its expression in blood correlating with disease recurrence and progression in patients, a finding that warrants further testing of this marker.
This marker was detected amongst patients regardless of whether or not they were considered clinically disease free, indicating that these stem -like circulating cells remain for long periods in the blood. A role for ABCB5 cells in disease spread has been demonstrated in mouse -to-mouse transplantation experiments, where circulating ABCB5 expressing tumour cells were shown to be capable of initiating metastatic disease after transplantation into donor mice 23 .
Besides ABCB5, MLANA expression was also a potential predictor of recurrence events in our patient cohort. Since ABCB5 positive cells do not co-express MLANA 24 , circulating cells must therefore include both stem and non-stem cell phenotypes during recurrence. This may reflect a change in stem cell to a non-stem cell phenotype during formation of the metastatic tumour 43 . Previous studies described MLANA expression as correlating with disease stage 25 , and in this study both MLANA and ABCB5 expression correlated with disease stage, with expression more common in advanced (stage III-IV) than in early stage (stage 0-II) patients.
In fact, removal of a clinically measurable metastasis significantly reduced the expression of Pax3d, ABCB5 and MLANA in stage III-IV patients, signifying the importance of metastases in maintaining the hematogenous spread of tumour cells 44, 7 .
Utilising these markers, circulating tumour cells were detected at all disease stages long after surgical treatment, even when a patient was considered clinically disease free. Thus, as found in previous studies of circulating tumour cells 42, 45 , the mere presence of circulating tumour cells does not always correlate with disease stage or metastatic recurrence, and additional markers are required to stratify those early stage patients likely to have disease progression.
In our study MCAM expression correlated with increased tumour burden, a result consistent with recent in vivo studies with nude mice that revealed a significant correlation between MCAM expression and the formation of metastases 46 . MCAM was also the most suitable marker for monitoring response to therapy and indicates, presumably, ineffective eradication of circulating melanoma cells, evidenced here by an increase in the incidence of MCAM expression in patients with a negative treatment outcome. MCAM expression could therefore be used to monitor treatment resistance or risk of relapse. Given MCAM expression is thought to play a role in cell-cell and cell-matrix interactions during formation of metastases, Table 3 Table 5 -MCAM expression in the peripheral blood of stage IV melanoma patients in relation to clinical outcome.
MCAM expression % (n)
Clinical Outcome + -N Negative (disease progression and/or death) 43 (17) 58 (23) 40
Positive (disease remained stable or tumour size reduced) 9 (2) 91 (20) 
